Evidence of transplacental passage of hydroxychloroquine in humans

Costédoat-Chalumeau, Nathalie; Amoura, Zahir; Aymard, Guy; Hong, Du Le Thi; Wechsler, B.; Vauthier, D.; Dermer, M E; Darbois, Y; Piette, Jean‐Charles

doi:10.1002/art.10150

Cited by 107 publications

(54 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CQ may afford some neuroprotective effects against brain inflammation as highlighted from studies on the actions of this drug against the HIV-1 viral coat protein in mice (Ashraf et al 2014). The amount of HCQ that is secreted in breast milk is limited to the extent that concentrations in cord blood are similar to those in blood (Costedoat-Chalumeau et al 2002). An issue has been raised about the possible pigmented changes in foetal tissues due to deposits of HCQ and/or its metabolites (Borden and Parke 2001).…”

Section: Excretion In Breast Milk and Transplacental Passagementioning

confidence: 97%

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

et al. 2015

View full text Add to dashboard Cite

HCQ and CQ have a good reputation for being effective and relatively safe treatments in SLE, mild-moderate RA and Sjøgren's syndrome. There is need for (a) more information on their mode of action in relation to the control of these diseases, (b) scope for developing formulations that have improved pharmacokinetic and therapeutic properties and safety, and (c) further exploring their use in drug combinations not only with other disease modifying agents but also with biologics.

show abstract

Section: Excretion In Breast Milk and Transplacental Passagementioning

confidence: 97%

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

et al. 2015

View full text Add to dashboard Cite

show abstract

“…utilisation d'une contraception efficace chez la femme en â ge de procré er ; en cas de dé sir de grossesse le MTX est arrê té 4-6 mois avant la conception compte tenu de la pharmacociné tique du MTX et supplé mentation en acide folique poursuivie ; en cas de dé couverte d'une grossesse pendant le traitement, le MTX doit ê tre arrê té le plus rapidement possible et une é valuation du risque doit ê tre effectué e au cas par cas, en tenant compte notamment de la chronologie de la prise et de la posologie (les malformations ont é té observé es dè s 12,5 mg en dose totale et la pé riode critique concerne au moins le 1er trimestre) ; en cas de poursuite de la grossesse, est né cessaire un dé pistage pré natal ciblé sur les malformations dé crites [23,24].…”

Section: Méthotrexateunclassified

Polyathrite rhumatoïde et grossesse

Florea

Job-Deslandre

2008

La Presse Médicale

View full text Add to dashboard Cite

“…Different studies have demonstrated that CQ, HCQ and their metabolites are excreted and can be found in breast milk, moreover transplacental passage has been also observed [90,91].…”

Section: Pharmacokinetics and Pharmacodynamics Of Antimalarials: Can mentioning

confidence: 99%

Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs

Piscianz

Cuzzoni

Sharma

et al. 2018

CMC

View full text Add to dashboard Cite

The story of antimalarials as antinflammatory drugs dates back few centuries. Chinin, the extract of the Cinchona bark, has been exploited since the 18th century for its antimalarial and antifebrile properties. Later, during the Second World War, the broad use of antimalarials allowed arguing their antirheumatic effect on soldiers. Since then, these drugs have been broadly used to treat Systemic Lupus Erythematosus, but, only recently, the molecular mechanisms of action have been partly clarified.The inhibitory action on vacuole function and trafficking has been considered for decades the main mechanism of the action of antimalarials, affecting the activation of phagocytes and dendritic cells. In addition, chloroquine is also as a potent inhibitor of autophagy, providing another possible explanation of its antinflammatory action. However, much attention has been recently devoted to the action of antimalarials on the so-called cGAS-STING pathway deputed to the sensing of nucleic acid and to the production of type 1 interferons. This pathway is a fundamental mechanism for host defence, since it is able to detect microbial DNA and RNA and induce the immune response that will lead to the production of interferons. Of note, genetic defects in disposal of nucleic acids lead to inappropriate activation of the cGAS-STING pathway and inflammation. These disorders, named type I interferonopathies, represent a valuable model to study the antinflammatory potential of antimalarials.We will discuss possible development of antimalarials to improve the treatment of type I interferonopathies and, likely multifactorial disorders characterised by interferon inflammation, such as systemic lupus erythematosus.

show abstract

Evidence of transplacental passage of hydroxychloroquine in humans

Cited by 107 publications

References 10 publications

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases

Polyathrite rhumatoïde et grossesse

Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs

Contact Info

Product

Resources

About